One of the world’s largest manufacturers and distributors of medical and surgical products such as needles, syringes and sharps disposal units is the latest company to benefit from an ongoing recovery in demand for non-urgent surgical procedures.

The biopharmaceutical company is testing with multiple U.S. military branches at Northern Strike to provide Bexson’s BB106 ketamine therapy for pain management for contested environments.

The biotech company shuffled deals around yesterday, dropping a four-year collaboration with Israel’s Entera Bio and picking a new partner in Massachusetts-based TScan Therapeutics.

The deal gives Moderna access to Generation Bio’s proprietary drug delivery system and DNA technology to develop drugs targeting immune cells and the liver.

Research engineers from the Massachusetts Institute of Technology have found a way to prevent scar tissue from disabling implantable devices. If established as safe and effective in humans, this technology could prove transformative in treating many diseases, such as diabetes.